Cell freezing medium is a complete cell freezing media for mammalian cell cultures.
Most classic formulations of cell freezing media containing dimethyl sulfoxide (DMSO) as the active freezing agent. However, since it is known that DMSO is a mutagen and carcinogen, DMSO-free formulations are becoming popular for stem cell applications. This is an especially critical consideration for cells being used in translational research or clinical applications. Moreover, media formulations that are manufactured under GMP compliance and have drug-master files registered with government regulatory agencies provide added value for regenerative medicine use.
Market Analysis and Insights: Global Cell Freezing Media for Cell Therapy Market
Due to the COVID-19 pandemic, the global Cell Freezing Media for Cell Therapy market size is estimated to be worth US$ 91 million in 2022 and is forecast to a readjusted size of US$ 198.8 million by 2028 with a CAGR of 13.8% during the forecast period 2022-2028. Fully considering the economic change by this health crisis, With FBS accounting for % of the Cell Freezing Media for Cell Therapy global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Human Embryonic Stem Cells segment is altered to an % CAGR throughout this forecast period.
Market competition is intense. BioLife Solutions, Thermo Fisher Scientific, Merck, Cytiva, Zenoaq, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers. The Top 5 manufacturers occupied 84.84% of global market share in 2021.
Global Cell Freezing Media for Cell Therapy Scope and Segment
Cell Freezing Media for Cell Therapy market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Cell Freezing Media for Cell Therapy market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
With FBS
Without FBS
Segment by Application
Human Embryonic Stem Cells
CAR-T Cell Therapy
Neural Stem Cell Therapy
Mesenchymal Stem Cell Therapy
Hematopoietic Stem Cell Transplantation
Others
By Company
BioLife Solutions
Thermo Fisher Scientific
Merck
Cytiva
Zenoaq
WAK-Chemie Medical
Sartorius
Akron Biotechnology
Sansheng Bio
Youkang Bio
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE